OC
TOVX icon

Oppenheimer & Co’s Theriva Biologics TOVX Stock Holding History

Oppenheimer & Co’s Portfolio TOVX Stock Details TOVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-1
Closed -$15K – 1546
2014
Q4 		$15K Hold
1
– – ﹤0.01% 1387
2014
Q3 		$18K Buy
+1
New +$16.3K ﹤0.01% 1403

Other funds holding TOVX

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TC
TFS Capital West Chester, Pennsylvania $255M AUM 32.31% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Oppenheimer & Co's TOVX Position: Q1 2015 in Review

Oppenheimer & Co sold out of Theriva Biologics (TOVX) in Q1 2015, closing a stake of 1 share — an estimated $15K sold.

Oppenheimer & Co first reported a position in TOVX in Q3 2014 and held it in 2 quarters. The position peaked at $18K in Q3 2014. 38 funds tracked by Wall St. Rank hold TOVX as of Q1 2015.

  • Oppenheimer & Co reported no remaining Theriva Biologics position as of Q1 2015 after selling out during the quarter.
  • Oppenheimer & Co sold 1 Theriva Biologics share in Q1 2015, an estimated $15K.
  • Oppenheimer & Co first reported a position in Theriva Biologics in Q3 2014 and held it in 2 quarters.
  • Oppenheimer & Co's Theriva Biologics position peaked at $18K in Q3 2014.
  • 38 funds tracked by Wall St. Rank held Theriva Biologics as of Q1 2015.

Based on Oppenheimer & Co's 13F filing for Q1 2015, filed 8 May 2015.